H.C. Wainwright starts coverage of Galectin Therapeutics with 'buy'

H.C. Wainwright initiates coverage of drug developer Galectin Therapeutics GALT.O with 'buy' rating; sets PT at $6, which is ~233.3% upside on stock's last close

Brokerage says Galectin is currently developing belapectin to treat chronic liver disease called metabolic dysfunction-associated steatohepatitis (MASH), which can progress to cirrhosis, liver failure and liver cancer

H.C. Wainwright says GALT's belapectin is only therapy in development for MASH cirrhosis

"Initial clinical trials exhibited compelling trends towards preventing and halting signs and symptoms of the disease," brokerage says

Including session's moves, stock up ~45% YTD